Stem Cell Transplantation is good for Juvenile Myelomonocytic Leukemia Patients
A group of medical researchers suggest using stem cell transplantation to treat patients with a serious but a very rare form of chronic blood cancer 'Juvenile Myelomonocytic Leukemia' (JMML) has shown improved results. The study has been published in the journal Blood.
[adsense:336x280:8701650588]
Researchers at the Children's Hospital Los Angeles (CHLA), led by Dr. Hisham Abdel-Azim, looked at the children with Juvenile Myelomonocytic Leukemia (JMML) who underwent cell transplantation at the hospital and noticed that all of them were alive and in clinical remission. Abdel-Azim said that it was also possible that administering conventional dose chemotherapy, before cell transplantation, to patients with more progressive disease may have contributed to improved outcomes. He added that a follow up clinical trial was warranted to confirm these promising findings.
He said that the lack of transplant-related mortality in the group of children we studied at the Children's Center for Cancer and Blood Diseases at the hospital suggested that BUMEL (Intravenous Busulfan and Melphalan) may represent a successful cell transplantation high-dose chemotherapy regimen.
Subscribe to PharmaTutor News Alerts by Email >>